The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.
Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.
Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
The diagnostics company said the number of tests accessioned during the quarter grew 60 percent year over year.
The test analyzes microRNA expression in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.
Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.
In Science this week: convergent evolution in bird hemoglobin, and more.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.